Prostate-specific antigen and (free prostate-specific antigen/ prostate-specific antigen) ratio in patients with Benign Prostatic Hyperplasia and Prostate Cancer


Background: Prostate cancer is one of the most common cancers in menworldwide. Many markers are suggested as markers of prostate cancer with differentspecificity and sensitivity.Objective : The present study’s main aim is to examine the possible utility ofprostate-specific antigen indices as markers of prostate cancer.Methods: A case-control study was conducted in the Department of Chemistry andBiochemistry, College of Medicine, Al- Nahrain University, Baghdad, Iraq from July2018 till March 2019, includes 84 subjects divided into three groups:Twenty Four patients with prostate cancer (PCA), thirty patients with benignprostatic hyperplasia (BPH) and thirty healthy subjects as a control group wereexamined in this study.Thirty healthy volunteer subjects were asked to be involved in this study as a controlgroup. Blood samples from these patients were collected before obtaining a prostaticbiopsy. Serum PSA, fPSA levels were quantified by the ELISA technique.Results: PSA cut-off value was found to be more than 9.57 ng/ml for Prostate Cancerpatients, values range between 3.17 - 9.57 ng/ml for BPH patients and cut-off valuefor control was found to be less than 3.17 ng/ml, while serum (fPSA/PSA) % cut-offvalue was less than 11.1% for Prostate Cancer patients, values range between 11.1% -31 % for BPH patients, and cut-off value was greater than 31% for the control group.Conclusion: There is a highly significant difference in serum PSA levels and(fPSA/PSA)% between the prostate cancer and control groups. Body mass indexshowed an inverse association with the risk of prostate cancer.